Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
H.C. Wainwright has confirmed a Buy rating and a $50 price target for Aligos Therapeutics following a recent update on its Phase 2 B-SUPREME clinical trial evaluating pevifoscorvir sodium for chronic hepatitis B. The trial's progress and the company’s strategic initiatives in metabolic liver disease have strengthened investor confidence, while the …
Piper Sandler has reaffirmed an Overweight recommendation for Align Technology, underpinned by a 3.3% year-over-year rise in U.S. clear aligner volumes during December and the likelihood of upward adjustments in earnings forecasts. The firm's target price of $200 signals an 18% gain from current stock levels, with valuation metrics indicating poten…
H.C. Wainwright reaffirmed its Buy stance on Invivyd Inc., maintaining a $10 price target, following a recent dialogue with the company’s leadership. This valuation implies substantial upside relative to the current stock price, reflecting confidence in Invivyd’s forthcoming Phase 3 results for VYD2311 and growth from the PEMGARDA franchise. The co…
In 2025, TikTok, a ByteDance-owned short-video platform, continued to hold its position as the second-most-downloaded app in the United States, overshadowing ongoing political challenges and regulatory scrutiny related to its Chinese ownership. Other apps linked to Chinese companies, including ByteDance’s CapCut and e-commerce site Temu, also maint…
UBS Group AG, the world's largest wealth manager, is exploring the introduction of cryptocurrency investment options for select private banking clients, starting in Switzerland. The bank is in the process of selecting partners to facilitate trading in digital assets such as Bitcoin and Ether, with possible future expansion to Asia-Pacific and the U…
As President Yoweri Museveni begins his seventh term at 81 years old, his son Muhoozi Kainerugaba, head of Uganda’s military, is increasingly poised to assume leadership. Muhoozi’s firm handling of opposition suppression, including internet blackouts and arrests, and strategic moves within the military and ruling party structure have strengthened h…
SLB reported better-than-expected adjusted earnings for Q4, driven by its recent acquisition of ChampionX. The company plans to deliver over $4 billion to shareholders through dividends and buybacks in 2026, signaling confidence despite regional market softness. Investor interest has heightened following developments in Venezuela's oil sector, posi…
H.C. Wainwright has upheld its Buy rating and set a $22.00 price objective for Redwire stock, forecasting significant upside driven by geopolitical dynamics primed to enhance the company's revenue streams by 2026. The firm highlights strong year-to-date performance and transformative defense contract opportunities as key catalysts for Redwire's fut…
KeyBanc has reaffirmed its Overweight rating on JFrog, projecting a 39% upside with a $79 price target ahead of the company’s Q4 earnings announcement scheduled for February 12. The firm highlights growth opportunities driven by AI software development activity and increasing adoption of JFrog’s security products. Broader industry support from anal…
H.C. Wainwright upgraded its price target for Corcept Therapeutics to $105 from $90, maintaining a Buy rating based on encouraging results from the Phase 3 ROSELLA study evaluating relacorilant in platinum-resistant ovarian cancer. The trial demonstrated a significant improvement in overall survival when relacorilant was combined with nab-paclitaxe…
H.C. Wainwright has increased its price target for Spire Global to $19 from $14, citing heightened defense budgets among NATO nations as a major factor influencing this reassessment. Despite a 64.1% year-to-date stock gain outpacing the Russell 2000 by a wide margin, the brokerage foresees continued growth for Spire Global into 2026 fueled by strat…
H.C. Wainwright reaffirmed its Buy rating on uniQure, with a $70 price target signaling significant upside potential despite regulatory hurdles. The firm's outlook follows in-depth meetings with uniQure's leadership, focusing on AMT-130 for Huntington's disease and upcoming FDA engagements. While uniQure faces financial challenges, its strong liqui…
Rosenblatt Securities elevated Intel's price target from $25 to $30 while retaining a Sell rating, reflecting cautious optimism amid the semiconductor firm's strong share price gains and ongoing operational hurdles. Intel shares have surged notably this year but face capacity constraints and a delayed timeline for new foundry customers, resulting i…
H.C. Wainwright has reduced its price target for CorMedix to $13 from $18 while maintaining a Buy rating. The adjustment follows updated 2026-2027 DefenCath sales guidance that influenced the stock's recent pullback. Despite a 36% drop year-to-date, the company's strong gross margins and low P/E ratio underscore its undervaluation. The stock's futu…
Northland has upgraded Intel's price target from $46 to $54, maintaining an Outperform rating driven by recent strong earnings and the company's strategic significance in the U.S. Although first-quarter guidance reflects capacity limitations and supply constraints persist, Intel has produced an impressive 151.83% return over the last year. Broader …
Chinese regulators are contemplating tighter regulations for mainland companies aiming to list shares on the Hong Kong Stock Exchange. This move comes amid concerns about the quality of recent listings following a surge in offshore fundraising. Among the measures discussed is the introduction of a minimum market capitalization requirement and close…
H.C. Wainwright has adjusted its price objective for Plus Therapeutics Inc. from $2.00 down to $1.00 after a recent equity offering by the company. Despite this reduction, the investment bank kept its Buy recommendation, citing upside potential from Plus Therapeutics' current trading price well below its yearly high. The company aims to reach sever…
In response to extensive Russian strikes that have incapacitated power supply to around one million Ukrainians during a severe cold spell, the European Union is delivering emergency generators to restore electricity to essential services. Concurrently, France is initiating a coordination call with international allies to enhance support for Ukraine…
U.S. stock futures declined with heightened geopolitical tensions and notable company earnings reports affecting investor sentiment. Intel's substantial quarterly loss and cautious outlook contrasted with Nvidia's modest gains following potential Chinese regulatory approvals for AI chips. Meanwhile, airline stocks dropped due to widespread winter w…
The energy ministries of Kazakhstan and the United States recently convened to explore avenues for cooperation focusing on Kazakhstan's oil and gas sector. Kazakhstan, a significant player in global energy markets, has faced recent production setbacks due to operational incidents and security disruptions affecting key infrastructure. U.S. energy co…
Barclays' analysis frames the swift resolution of the Greenland tariff dispute as evidence of the U.S. administration’s low tolerance for disruption in financial markets. Despite initial market jitters triggered by proposed tariffs impacting NATO allies, equity markets stabilized quickly, reflecting investor resilience amid elevated positioning and…
Shares of New Era Energy & Digital experienced significant fluctuation over two trading sessions after the company filed a mixed securities shelf registration with the SEC enabling potential capital raising of up to $350 million. Initial investor optimism gave way to concerns over dilution risks linked to future securities issuance under this shelf…
Canaccord Genuity has raised its price target on LSI Industries to $27, reflecting confidence in the company’s sustained revenue growth and prudent capital management. Despite a slight earnings per share miss in its recent quarterly report, LSI’s top-line results exceeded expectations, signaling positive momentum in its operational execution. The s…
Jefferies has updated its perspective on German automotive suppliers, highlighting a challenging environment in 2026 marked by subdued production, heightened competition, and constrained prospects for sales and margin improvements. Despite the overall difficult market forecast, Schaeffler emerges as Jefferies’ preferred investment due to its strate…
Canaccord Genuity increased its price target for Corcept Therapeutics to $100 from $99, maintaining a Buy rating based on encouraging clinical results for relacorilant in treating platinum-resistant ovarian cancer (PROC). Despite regulatory challenges in other indications, the company remains financially robust with expectations for substantial rev…
